SMN1 and proximal spinal muscular atrophy: In the context of SMA, CPPs such as Pip6a, RXR peptides, and DG9 have shown promising results by enhancing cellular uptake and crossing the blood-brain barrier, leading to better restoration of SMN levels, prolonged survival, and improved phenotypes in mouse models [169,170,171].